跳至主要内容
临床试验/NCT04170075
NCT04170075已完成不适用

A Novel Therapeutic Intervention to Restore Health and Functioning in Persons With Chemotherapy-Induced Peripheral Neuropathy

OHSU Knight Cancer Institute2 个研究点 分布在 1 个国家目标入组 38 人开始时间: 2019年8月5日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
38
试验地点
2
主要终点
Adverse events

研究概览

简要总结

This clinical trial studies how well whole body vibration works in improving the health and functioning of participants with chemotherapy-induced peripheral neuropathy. Peripheral neuropathy is a condition caused by exposure to chemotherapy drugs that may involve numbness/tingling and/or pain in the hands and feet, which can have adverse effects on daily life. Whole body vibration may cause weight loss and improve mobility and pain levels in cancer survivors who report symptoms of peripheral neuropathy.

详细描述

PRIMARY OBJECTIVES:

I. Determine the feasibility and safety of whole body vibration (WBV) in adult cancer survivors with chemotherapy-induced peripheral neuropathy (CIPN).

II. Determine the effect of WBV training on physical functioning in adult cancer survivors with CIPN.

III. Explore the effect of WBV training on symptom relief (neuropathy symptoms, pain, fatigue) and readiness to exercise in adult cancer survivors with CIPN.

OUTLINE: Participants are randomized to 1 of 2 groups.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Supportive Care
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Histologically confirmed cancer stage I-IIIc (confirmed by self-report on the Health History Questionnaire. If the patient is unable to confirm, we will send a letter to their physician to confirm for this criterion)
  • Previous chemotherapy within five years of enrollment (confirmed by self-report on the Health History Questionnaire. If the patient is unable to confirm, we will send a letter to their physician to confirm for this criterion)
  • Presence of mild-very severe CIPN symptoms (confirmed by assessment using the Patient-Reported Outcomes [PRO]-Common Terminology Criteria for Adverse Events [CTCAE] criteria)
  • Age 18 years or older at enrollment (confirmed by self-report on the Health History Questionnaire)

排除标准

  • Body weight > 275 pounds (confirmed by self-report on the Health History Questionnaire)
  • A medical condition, movement or neurological disorder, or medication use that contraindicates participation in low intensity exercise and/or WBV (confirmed by self-report on the Health History Questionnaire, and by physician clearance, if in the professional opinion of the Principal Investigator, Dr. Kerri Winters-Stone, contraindications other than those identified by the patient or physician are present, she may consider the participant ineligible.)
  • Presence of any known metastases (confirmed by self-report on the Health History Questionnaire. If the patient is unable to confirm, we will send a letter to their physician to confirm for this criterion)
  • Adjuvant treatment for cancer within previous six weeks, other than hormone blocking, targeted or immunotherapy (confirmed by self-report on the Health History Questionnaire. If the patient is unable to confirm, we will send a letter to their physician to confirm for this criterion)

结局指标

主要结局

Adverse events

时间窗: Weekly up to 12-weeks

An in-house survey will ask about adverse events (e.g., bone pain, nausea) that occur during the intervention. The number of discrete moderate and severe adverse events will be summed as a single variable.

Accrual

时间窗: Up to 12-weeks

The number of participants enrolled during the recruitment period.

Adherence

时间窗: Up to 12-weeks

Adherence = % of sessions attended and compliance = % of each session completed.

Compliance

时间窗: Up to 12-weeks

Compliance = % of each session completed.

次要结局

  • Functional balance-sway amount(0, 12 weeks)
  • Symptoms of chemotherapy-induced peripheral neuropathy(0, 12 weeks)
  • Body mass index(0, 12 weeks)
  • Functional balance-sway velocity(0, 12 weeks)
  • Objective physical function(0, 12 weeks)
  • Functional mobility(0, 12 weeks)
  • Fatigue Visual Analog Scale(Before and after every whole body vibration session, up to 2 times per day, 7 days per week, for 12 weeks)
  • Patient Reported Outcomes Measurement Information System (PROMIS) fatigue scale(0, 12 weeks)
  • Perceived physical function(0, 12 weeks)
  • Exercise readiness(1, 12 weeks)
  • Functional balance-sway area(0, 12 weeks)
  • Brief Pain Inventory(0, 12 weeks)
  • Pain Visual Analog Scale(Before and after every whole body vibration session, up to 2 times per day, 7 days per week, for 12 weeks)
  • Gait(0, 12 weeks)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Kerri Winters

Principal Investigator

OHSU Knight Cancer Institute

研究点 (2)

Loading locations...

相似试验